Haijiao Lu

539 total citations
16 papers, 384 citations indexed

About

Haijiao Lu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Haijiao Lu has authored 16 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Haijiao Lu's work include Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Research Studies (3 papers) and Ferroptosis and cancer prognosis (3 papers). Haijiao Lu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Research Studies (3 papers) and Ferroptosis and cancer prognosis (3 papers). Haijiao Lu collaborates with scholars based in China, Italy and Spain. Haijiao Lu's co-authors include Zhuang Yu, Mei‐Chun Cai, Jie Wu, Pengfei Ma, Xiaojing Zhao, Yujie Fu, Guanglei Zhuang, Minjiang Chen, Shengzhe Zhang and Jing Wang and has published in prestigious journals such as ACS Nano, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Haijiao Lu

14 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haijiao Lu China	8	258	112	91	85	59	16	384
Tarig Osman Norway	11	165 0.6×	60 0.5×	60 0.7×	70 0.8×	46 0.8×	22	329
Ileine M. Sanchez United States	3	297 1.2×	130 1.2×	103 1.1×	113 1.3×	55 0.9×	6	361
Debora M.I. Fersching Germany	8	137 0.5×	54 0.5×	99 1.1×	46 0.5×	159 2.7×	8	334
Ikei S. Kobayashi Japan	9	124 0.5×	77 0.7×	109 1.2×	122 1.4×	54 0.9×	24	337
Conroy O. Field United States	6	366 1.4×	144 1.3×	115 1.3×	116 1.4×	82 1.4×	8	463
Sihui Yu China	8	153 0.6×	84 0.8×	47 0.5×	36 0.4×	81 1.4×	12	255
Woo Young Sun South Korea	9	82 0.3×	64 0.6×	162 1.8×	56 0.7×	127 2.2×	23	358
Éléonore Bettacchioli France	8	80 0.3×	92 0.8×	32 0.4×	13 0.2×	20 0.3×	14	253
Li Zheng China	7	231 0.9×	41 0.4×	43 0.5×	15 0.2×	81 1.4×	8	306
Yongjing Cheng China	11	86 0.3×	88 0.8×	24 0.3×	26 0.3×	19 0.3×	35	316

Countries citing papers authored by Haijiao Lu

Since Specialization

Citations

This map shows the geographic impact of Haijiao Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haijiao Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haijiao Lu more than expected).

Fields of papers citing papers by Haijiao Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haijiao Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haijiao Lu. The network helps show where Haijiao Lu may publish in the future.

Co-authorship network of co-authors of Haijiao Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Haijiao Lu. A scholar is included among the top collaborators of Haijiao Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haijiao Lu. Haijiao Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Cheng, Lei, Qiangsheng Hu, Yanan Wang, et al.. (2024). Cis‐Regulation of an m⁶A Eraser by an Insertion Variant Associated with Survival of Patients With Non‐Small Cell Lung Carcinoma. Advanced Science. 12(5). e2407652–e2407652.

Cai, Mei‐Chun, Jin Liu, Pengfei Ma, et al.. (2024). YY1 downregulation underlies therapeutic response to molecular targeted agents. Cell Death and Disease. 15(11). 862–862. 3 indexed citations

Chang, Qing, Jiaqi Li, Yan Zhu, et al.. (2024). Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease. Journal of Thoracic Disease. 16(11). 7546–7560.

Chen, Qi, Rong Xu, Cheng Zhou, et al.. (2024). Biomimetic Nanovesicles Synergize with Short-Term Fasting for Enhanced Chemotherapy of Triple-Negative Breast Cancer. ACS Nano. 18(50). 33875–33889. 13 indexed citations

Li, Jiaqi, Ruiying Zhao, Huiping Qiang, et al.. (2024). Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations. Frontiers in Oncology. 14. 1357231–1357231. 4 indexed citations

Lu, Haijiao, et al.. (2023). Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma. BMJ Open Respiratory Research. 10(1). e001878–e001878. 2 indexed citations

Li, Jiaqi, Hao Ji, Jialin Qian, et al.. (2023). Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study. Translational Lung Cancer Research. 12(12). 2505–2519. 4 indexed citations

Shi, Kaixuan, Haijiao Lu, Zhenfeng Zhang, et al.. (2022). Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer. Cell Death and Differentiation. 30(1). 195–207. 7 indexed citations

Cheng, Lei, Yanan Wang, Li‐Xin Qiu, et al.. (2022). mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. Journal of Translational Medicine. 20(1). 247–247. 15 indexed citations

10.

Zhang, Yi, Minhua Yu, Ying Jing, et al.. (2020). Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer. 124(2). 414–424. 50 indexed citations

11.

Lu, Haijiao, et al.. (2020). Identification of potential key genes and key pathways related to clear cell renal cell carcinoma through bioinformatics analysis. Acta Biochimica et Biophysica Sinica. 52(8). 853–863. 5 indexed citations

12.

Lu, Haijiao, Shengzhe Zhang, Jie Wu, et al.. (2018). Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. Clinical Cancer Research. 24(23). 6066–6077. 204 indexed citations

13.

Cai, Mei‐Chun, Minjiang Chen, Pengfei Ma, et al.. (2018). Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2‐mutant lung cancer. International Journal of Cancer. 144(4). 788–801. 22 indexed citations

14.

Lu, Haijiao, Zhuang Yu, Shihai Liu, et al.. (2015). CUGBP1 promotes cell proliferation and suppresses apoptosis via down-regulating C/EBPα in human non-small cell lung cancers. Medical Oncology. 32(3). 82–82. 14 indexed citations

15.

Yu, Zhuang, Haijiao Lu, Hongzong Si, et al.. (2015). A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer. PLoS ONE. 10(5). e0125517–e0125517. 20 indexed citations

16.

Yu, Zhuang, Xiaozheng Chen, Lianhua Cui, et al.. (2014). Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods. Asian Pacific Journal of Cancer Prevention. 15(21). 9367–9373. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact